Mobic / Meloxicam Mobic Manufacturer: Boehringer Ingelheim Pharmaceuticals Meloxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs), and is primarily used to reduce the pain, inflammation, and stiffness caused by osteoarthritis and rheumatoid arthritis. | Free legal Mobic / Meloxicam consultation
FDA NSAIDs Decision Memo SUBJECT: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk Executive Summary Following a thorough review of the available data we have reached the following conclusions regarding currently approved COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs)1 and the risk of adverse cardiovascular (CV) events:2
• The three approved COX-2 selective NSAIDs (i.e., celecoxib, rofecoxib, and valdecoxib) are associated with an increased risk of serious adverse CV events compared to placebo. The available data do not permit a rank ordering of these drugs with regard to CV risk.
• Data from large long-term controlled clinical trials that have included a comparison of COX-2 selective and non-selective NSAIDs do not clearly demonstrate that the COX-2 selective agents confer a greater risk of serious adverse CV events than non-selective NSAIDs.
|
Stevens Johnson Syndrome
Complete and submit the following information. Fields with (*) are required.
If you prefer, you may contact us at: (817) 334-0762 or toll free at (800) 803-3784.
This information will be kept private and confidential and used for the sole purpose of evaluating your case.
Please note that without a phone number or e-mail address, we will not be able to contact you.
You will be contacted by an attorney or paralegal, who is experienced in the area of drug injury law.
|
|